retatrutide regulatory approval FDA Status 2026: Everything We Know So Far This weight-loss drug hasn't been

These approaches work well when speed matters and when there is defined endpoint for treatment

Journal of Clinical Endocrinology & Metabolism , 91(12), 4792-4797

Instead of paying a standard $25 or $50 copay, consumers may be responsible for 20% to 50% of the drugs cost each month

AstraZeneca last year licensed Chinese company Eccogene's experimental oral drug, which has since moved into mid-stage development.

Half-life: SITAGLIPTIN Elimination Half-Life (t) in healthy subjects (60 mg single dose): Once administered at 100 mg, the elimination half-life (t) of sitagliptin in healthy subjects is approximately 12.4 hours